Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 6/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SNCA | P37840 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | RHOA | P61586 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 3/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL527276 | 1.00 | CYP3A4 (0.43) | CYP3A4TSHRMAPTCACNA1BAPBA1 | |
| SCHEMBL9331939 | 0.91 | CYP3A4 (0.38) | CYP3A4TSHRMAPTCACNA1BAPBA1 | |
| SCHEMBL527277 | 0.91 | CYP3A4 (0.38) | CYP3A4TSHRMAPTCACNA1BAPBA1 | |
| SCHEMBL729015 | 0.84 | CYP3A4 (0.43) | CYP3A4TSHRMAPTCACNA1BAPBA1 | |
| SCHEMBL19033480 | 0.82 | — | — | |
| SCHEMBL10940301 | 0.82 | — | — | |
| SCHEMBL9191412 | 0.80 | — | — | |
| SCHEMBL4033322 | 0.78 | CYP3A4 (0.39) | CYP3A4TSHRMAPTCACNA1BAPBA1 | |
| SCHEMBL9242763 | 0.78 | CYP3A4 (0.39) | CYP3A4TSHRMAPTCACNA1BAPBA1 | |
| SCHEMBL11434609 | 0.77 | CYP3A4 (0.38) | CYP3A4TSHRMAPTCACNA1BAPBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3206695-A1 | SCALABLE SYNTHESIS OF REDUCED TOXICITY DERIVATIVE OF AMPHOTERICIN B | The Board of Trustees of the University of Illionis (US) | 2017-08-23 | — | — | EP | claimed |
| US-20170233427-A1 | SCALABLE SYNTHESIS OF REDUCED TOXICITY DERIVATIVE OF AMPHOTERICIN B | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2017-08-17 | — | — | US | claimed |
| WO-2016061437-A1 | SCALABLE SYNTHESIS OF REDUCED TOXICITY DERIVATIVE OF AMPHOTERICIN B | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2016-04-21 | — | — | WO | claimed |
| US-10683318-B2 | Scalable synthesis of reduced toxicity derivative of amphotericin B | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2020-06-16 | — | — | US | disclosed |
| US-20190127412-A1 | SCALABLE SYNTHESIS OF REDUCED TOXICITY DERIVATIVE OF AMPHOTERICIN B | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2019-05-02 | — | — | US | disclosed |
| US-10087206-B2 | Scalable synthesis of reduced toxicity derivative of amphotericin B | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-10-02 | — | — | US | disclosed |
| EP-3206695-A1 | SCALABLE SYNTHESIS OF REDUCED TOXICITY DERIVATIVE OF AMPHOTERICIN B | The Board of Trustees of the University of Illionis (US) | 2017-08-23 | — | — | EP | disclosed |
| US-20170233427-A1 | SCALABLE SYNTHESIS OF REDUCED TOXICITY DERIVATIVE OF AMPHOTERICIN B | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2017-08-17 | — | — | US | disclosed |
| WO-2016061437-A1 | SCALABLE SYNTHESIS OF REDUCED TOXICITY DERIVATIVE OF AMPHOTERICIN B | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2016-04-21 | — | — | WO | disclosed |
| EP-2890693-A1 | PYRAZOLE DERIVATIVES AS P38 MAP INHIBITORS | Respivert Limited (GB) | 2015-07-08 | — | — | EP | disclosed |
| EP-2491022-B1 | DIAZEPAN DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | HOFFMANN LA ROCHE (CH) | 2014-12-31 | — | — | EP | disclosed |
| US-20030195232-A1 | 2,3-Disubstituted pyridine derivative, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor | KAWASAKI MOTOJI (JP) | 2003-10-16 | — | — | US | disclosed |
| WO-1997036865-A1 | PROCESS FOR PRODUCING INTERMEDIATE COMPOUNDS FOR THE PRODUCTION OF FACTOR Xa INHIBITORS | BOEHRINGER MANNHEIM GMBH (DE) | 1997-10-09 | — | — | WO | disclosed |
| US-5254681-A | Process for preparing monobactames and their intermediate product | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 1993-10-19 | — | — | US | disclosed |
| EP-0411541-A2 | Process for preparing monobactames and their intermediate product | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 1991-02-06 | — | — | EP | disclosed |
| EP-0124216-B1 | C-20- AND C-23-MODIFIED MACROLIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1988-10-26 | — | — | EP | disclosed |
| EP-0104028-B1 | C-20-MODIFIED MACROLIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1988-08-03 | — | — | EP | disclosed |
| US-4518607-A | FUNGICIDES, BACXTERICIDES AND ANTIPROTOZOA AGENTS | SYNTEX (U.S.A.) INC. (US) | 1985-05-21 | — | — | US | disclosed |
| EP-0124216-A1 | C-20- and C-23-modified macrolide derivatives | ELI LILLY AND COMPANY (US) | 1984-11-07 | — | — | EP | disclosed |
| EP-0104028-A1 | C-20-modified macrolide derivatives | ELI LILLY AND COMPANY (US) | 1984-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10683318-B2 | Scalable synthesis of reduced toxicity derivative of amphotericin B | ERG28, MANBA, CYP51A1 | CYP3A4 271/4885TSHR 4044/4885MAPT 3837/4885 |
| US-20170233427-A1 | SCALABLE SYNTHESIS OF REDUCED TOXICITY DERIVATIVE OF AMPHOTERICIN B | ERG28, MANBA, CYP51A1 | CYP3A4 271/4885TSHR 4044/4885MAPT 3837/4885 |
| US-10087206-B2 | Scalable synthesis of reduced toxicity derivative of amphotericin B | ERG28, MANBA, CYP51A1 | CYP3A4 271/4885TSHR 4044/4885MAPT 3837/4885 |
| US-20190127412-A1 | SCALABLE SYNTHESIS OF REDUCED TOXICITY DERIVATIVE OF AMPHOTERICIN B | ERG28, MANBA, CYP51A1 | CYP3A4 271/4885TSHR 4044/4885MAPT 3837/4885 |
| US-20030195232-A1 | 2,3-Disubstituted pyridine derivative, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor | NOX1, CYP4A11, PDE12 | CYP3A4 197/4885TSHR 3472/4885MAPT 4662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.